1. Home
  2. > Pharmaceutical Market Trends
LRRK2 Inhibitor - Pipeline Insight, 2022

LRRK2 Inhibitor - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6022135
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Understanding

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Overview
Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin, is a large multidomain protein kinase that includes leucine-rich repeats and a GTPase domain. LRRK2 is a 286 kDa complex scaffolding protein containing ankyrin, leucine-rich and WD40 repeats, and a catalytic core with Ras-Of-Complex (ROC) GTPase and serine-threonine kinase activities. Mutations in leucine-rich repeat kinase 2 (LRRK2) are the major genetic cause of autosomal-dominantly inherited Parkinson’s disease. Studies found that inhibiting the activity of LRRK2 kinase may benefit patients both with and without Parkinson disease-related mutation. Research and clinical development activities are going on toward the development of pharmacological inhibitors of LRRK2 kinase activity as a therapeutic intervention.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor R&D. The therapies under development are focused on novel approaches for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs Chapters
This segment of the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Emerging Drugs
• ION859: Ionis Pharmaceuticals
ION859 (formerly IONIS-BIIB7Rx), also known as BIIB094, is an investigational antisense medicine targeting Leucine Rich Repeat Kinase 2 (LRRK2) messenger ribonucleic acid (mRNA). It is designed to prevent the production of LRRK2 protein and is currently under Phase II clinical evaluation for Parkinson’s disease (PD). It is hypothesized that reduction of LRRK2 mRNA and, subsequently, reduced synthesis of LRRK2 protein will ameliorate the toxic effects of gain-of-function mutations as well as the primary pathology in PD patients without the LRRK2 mutation.

• DNL151: Denali Therapeutics
DNL151 is a potent, selective and brain-penetrant oral small molecule inhibitor of LRRK2. It is in Phase I clinical development for Parkinson’s disease. Denali Therapeutics is developing this drug in collaboration with Biogen. Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease.
Further product details are provided in the report……..

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor
There are approx. 8+ key companies which are developing the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor. The companies which have their Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Ionis Pharmaceuticals.

• Phases
This report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs.

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Insights
• Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs?
• How many Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Ionis Pharmaceuticals
• Denali Therapeutics
• Neuron23
• Voronoi
• E-Scape Bio

Key Products
• ION859
• DNL151
• Small molecule therapeutics
• VRN-01
• ESB-5070

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on